BostonGene and Exigent Genomic INsight Study
About this study
The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Four cohorts of 100 patients each will be studied over two years, focusing on treatment decisions and patient outcomes. This study seeks to demonstrate the clinical utility of genomic testing in guiding therapy for advanced cancer patients in community settings.
- Condition
- Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
- Sponsor
- BostonGene
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 8
- Minimum age: 18 years
- Study condition: Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
- Patients must have a confirmed malignancy of:
- Locally recurrent, unresectable, or metastatic breast cancer or; Unresectable stage III or metastatic non-small cell lung cancer or; Unresectable or metastatic melanoma or; Locally advanced or metastatic l sarcoma.
- Life expectancy \> 3 months as per the treating physician
- Willingness to provide informed consent
- Living in the United States at time of enrollment
- Agree to participate in genomic and molecular profiling
Exclusion 1
- not meeting the inclusion criteria
Where
7 sites, 7 recruiting
New Mexico Cancer Center
Albuquerque, New Mexico, United States
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, United States
Oncology Consultants
Houston, Texas, United States
Northwest Medical Specialities
Puyallup, Washington, United States
Highlands Oncology Group
Rogers, Arkansas, United States
Stockton Hematology Oncology Medical Group
Stockton, California, United States
and 1 more site on ClinicalTrials.gov
Contact
-
Rheanna Carter, MBA
650-773-0771 rheanna.carter@bostongene.com
Potential match only. Final eligibility is determined by the study team.